Morgan Stanley Viking Therapeutics, Inc. Transaction History
Morgan Stanley
- $1.59 Trillion
- Q3 2025
A detailed history of Morgan Stanley transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,729,117 shares of VKTX stock, worth $148 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,729,117
Previous 3,247,694
14.82%
Holding current value
$148 Million
Previous $86.1 Million
10.66%
% of portfolio
0.01%
Previous 0.01%
Shares
25 transactions
Others Institutions Holding VKTX
# of Institutions
436Shares Held
66.6MCall Options Held
7.29MPut Options Held
3.89M-
Vanguard Group Inc Valley Forge, PA10MShares$398 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$240 Million0.01% of portfolio
-
State Street Corp Boston, MA4.51MShares$180 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY2.58MShares$103 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA2.1MShares$83.6 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.05B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...